{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:49:52Z","timestamp":1777625392989,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007048","name":"EEA Grants","doi-asserted-by":"publisher","award":["21-COP-0049"],"award-info":[{"award-number":["21-COP-0049"]}],"id":[{"id":"10.13039\/501100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027502","name":"East End Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027502","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","award":["773\/1\/11.01.2023"],"award-info":[{"award-number":["773\/1\/11.01.2023"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","award":["649\/1\/11.01.2024"],"award-info":[{"award-number":["649\/1\/11.01.2024"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","award":["882\/4\/12.01.2022"],"award-info":[{"award-number":["882\/4\/12.01.2022"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jpet.2025.103767","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:41:40Z","timestamp":1761928900000},"page":"103767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing local glioblastoma treatment via in vitro synergistic pairing of Janus kinase\/signal transducer and activator of transcription-3 inhibitor with antiepileptic drugs"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-1751","authenticated-orcid":false,"given":"Alexandra-Iulia","family":"B\u0103r\u0103ian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Raduly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Z\u0103noag\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan-Cezar","family":"Iacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Berindan-Neagoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-2286","authenticated-orcid":false,"given":"Ede","family":"Bodoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpet.2025.103767_bib1","first-page":"740","article-title":"Challenges and opportunities in newly diagnosed glioblastoma in the United Kingdom: a Delphi panel","volume":"11","author":"Bulbeck","year":"2024","journal-title":"Neurooncol Pract"},{"issue":"8","key":"10.1016\/j.jpet.2025.103767_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jpet.2025.103767_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200815","article-title":"Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors","volume":"13","author":"Guo","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103767_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/cancers11040469","article-title":"Pathological and molecular features of glioblastoma and its peritumoral tissue","volume":"11","author":"D\u2019Alessio","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/cancers14020443","article-title":"Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives","volume":"14","author":"Seker-Polat","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jpet.2025.103767_bib6","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3390\/ijms22126385","article-title":"Molecular mechanisms of drug resistance in glioblastoma","volume":"22","author":"Dymova","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jpet.2025.103767_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/biomedicines10040806","article-title":"The hallmarks of glioblastoma: heterogeneity, intercellular crosstalk and molecular signature of invasiveness and progression","volume":"10","author":"Torrisi","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.jpet.2025.103767_bib8","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpet.2025.103767_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123227","article-title":"Glioblastoma therapy: state of the field and future prospects","volume":"359","author":"Khiabani","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.jpet.2025.103767_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2016.09.034","article-title":"Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma","volume":"243","author":"Bastiancich","year":"2016","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.jpet.2025.103767_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma \u2013 taking the fight to the tumour","volume":"18","author":"van Solinge","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jpet.2025.103767_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120128","article-title":"Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma","volume":"287","author":"Mor\u00e1s","year":"2021","journal-title":"Life Sci"},{"issue":"23","key":"10.1016\/j.jpet.2025.103767_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313160","article-title":"Design of biopolymer-based interstitial therapies for the treatment of glioblastoma","volume":"22","author":"Pena","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.jpet.2025.103767_bib14","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1039\/D1BM00896J","article-title":"Local delivery to malignant brain tumors: potential biomaterial-based therapeutic\/adjuvant strategies","volume":"9","author":"Alghamdi","year":"2021","journal-title":"Biomater Sci"},{"issue":"22","key":"10.1016\/j.jpet.2025.103767_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214071","article-title":"In vivo applications of molecularly imprinted polymers for drug delivery: a pharmaceutical perspective","volume":"23","author":"B\u0103r\u0103ian","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.jpet.2025.103767_bib16","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.3390\/polym13213649","article-title":"Perspectives of molecularly imprinted polymer-based drug delivery systems in ocular therapy","volume":"13","author":"Bodoki","year":"2021","journal-title":"Polymers (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pat.6317","article-title":"Current advances in molecularly imprinted polymers and their release mechanisms in drug delivery systems","volume":"35","author":"Lawai","year":"2024","journal-title":"Polym Adv Technol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/mabi.201000206","article-title":"Affinity-based drug delivery","volume":"11","author":"Wang","year":"2011","journal-title":"Macromol Biosci"},{"key":"10.1016\/j.jpet.2025.103767_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2025.113825","article-title":"Recent advances in composite materials integrating molecularly imprinted polymers for targeted drug delivery systems","volume":"228","author":"Guo","year":"2025","journal-title":"Eur Polym J"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/polym14030640","article-title":"Molecularly imprinted polymers as state-of-the-art drug carriers in hydrogel transdermal drug delivery applications","volume":"14","author":"Lusina","year":"2022","journal-title":"Polymers (Basel)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40824-023-00388-5","article-title":"Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications","volume":"27","author":"Kang","year":"2023","journal-title":"Biomater Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103767_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/polym15040965","article-title":"Ruxolitinib-loaded imprinted polymeric drug reservoir for the local management of post-surgical residual glioblastoma cells","volume":"15","author":"B\u0103r\u0103ian","year":"2023","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jpet.2025.103767_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140025","article-title":"Targeting JAK\/STAT3 in glioblastoma cells using an alginate-PNIPAm molecularly imprinted hydrogel for the sustained release of ruxolitinib","volume":"298","author":"B\u0103r\u0103ian","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jpet.2025.103767_bib24","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/1538-7445.AM2016-3861","article-title":"Ruxolitinib inhibits STAT-3 activation in glioblastoma","volume":"76","author":"Fehling","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103767_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3340\/jkns.2019.0252","article-title":"The dose dependent effects of ruxolitinib on the invasion and tumorigenesis in gliomas cells via inhibition of interferon gamma-depended JAK\/STAT signaling pathway","volume":"63","author":"Delen","year":"2020","journal-title":"J Korean Neurosurg Soc"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/cancers13030437","article-title":"The role and therapeutic targeting of JAK\/STAT signaling in glioblastoma","volume":"13","author":"Ou","year":"2021","journal-title":"cancers (Basel)"},{"key":"10.1016\/j.jpet.2025.103767_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1098482","article-title":"Roles of STAT3 in the pathogenesis and treatment of glioblastoma","volume":"11","author":"Fu","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acsabm.2c00973","article-title":"Drug delivery systems for localized cancer combination therapy","volume":"6","author":"Woodring","year":"2023","journal-title":"ACS Appl Bio Mater"},{"issue":"5","key":"10.1016\/j.jpet.2025.103767_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.16880","article-title":"First-line antiepileptic drug treatment in glioma patients with epilepsy: levetiracetam vs valproic acid","volume":"62","author":"van der Meer","year":"2021","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.jpet.2025.103767_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/neuonc\/nov269","article-title":"Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy","volume":"18","author":"Armstrong","year":"2015","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103767_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103767_bib33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.seizure.2014.06.015","article-title":"Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review","volume":"23","author":"Yuan","year":"2014","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.jpet.2025.103767_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1634\/theoncologist.2014-0060","article-title":"Seizure prognosis in brain tumors: new insights and evidence-based management","volume":"19","author":"Vecht","year":"2014","journal-title":"Oncologist"},{"issue":"39","key":"10.1016\/j.jpet.2025.103767_bib35","doi-asserted-by":"crossref","first-page":"62989","DOI":"10.18632\/oncotarget.11379","article-title":"Molecular dissection of the valproic acid effects on glioma cells","volume":"7","author":"Hoja","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpet.2025.103767_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155636","article-title":"Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme","volume":"263","author":"Vatankhah","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jpet.2025.103767_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.687362","article-title":"Valproic acid: a promising therapeutic agent in glioma treatment","volume":"11","author":"Han","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/jpet.119.258129","article-title":"Downregulation of TrkB expression and signaling by valproic acid and other histone deacetylase inhibitors","volume":"370","author":"Dedoni","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103767_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib40","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002170","article-title":"Central nervous system distributional kinetics of selected histone deacetylase inhibitors","volume":"392","author":"Zhang","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","article-title":"The effects of antiepileptic drugs on the growth of glioblastoma cell lines","volume":"127","author":"Lee","year":"2016","journal-title":"J Neurooncol"},{"issue":"7961","key":"10.1016\/j.jpet.2025.103767_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","article-title":"Glioblastoma remodelling of human neural circuits decreases survival","volume":"617","author":"Krishna","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.jpet.2025.103767_bib46","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.jpet.2025.103767_bib48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"10.1016\/j.jpet.2025.103767_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103767_bib53","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/sj.cdd.4401661","article-title":"Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase","volume":"12","author":"Zamaraeva","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jpet.2025.103767_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103767_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3727\/096504007783338340","article-title":"Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines","volume":"16","author":"Ciusani","year":"2007","journal-title":"Oncol Res"},{"key":"10.1016\/j.jpet.2025.103767_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720981878","article-title":"Valproic acid enhanced apoptosis by promoting autophagy via Akt\/mTOR signaling in glioma","volume":"29","author":"Han","year":"2020","journal-title":"Cell Transplant"},{"issue":"4","key":"10.1016\/j.jpet.2025.103767_bib57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4103\/1735-5362.350240","article-title":"The effect of valproic acid on intrinsic, extrinsic, and JAK\/STAT pathways in neuroblastoma and glioblastoma cell lines","volume":"17","author":"Sanaei","year":"2022","journal-title":"Res Pharm Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","article-title":"Multicellular tumor spheroids: an underestimated tool is catching up again","volume":"148","author":"Hirschhaeuser","year":"2010","journal-title":"J Biotechnol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib61","first-page":"345","article-title":"Advanced cell culture techniques for cancer drug discovery","volume":"3","author":"Lovitt","year":"2014","journal-title":"Biology (Basel)"},{"issue":"5\u20136","key":"10.1016\/j.jpet.2025.103767_bib62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","article-title":"Three-dimensional cell culture: the missing link in drug discovery","volume":"18","author":"Breslin","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jpet.2025.103767_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116931","article-title":"Insights into 2D and 3D cell culture models for nanoparticle-based drug delivery to glioblastoma","volume":"237","author":"Dabkevi\u010di\u016bt\u0117","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2025.103767_bib64","article-title":"Live-cell imaging and analysis of 3D spheroids in hypoxia- and radiotherapy-related research","volume":"51","author":"Beckers","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib65","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1038\/s41598-019-41408-6","article-title":"Elucidation of in vitro cellular steps induced by antitumor treatment with plasma-activated medium","volume":"9","author":"Chauvin","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103767_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2015.00181","article-title":"What is synergy? The Saariselk\u00e4 agreement revisited","volume":"6","author":"Tang","year":"2015","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103767_bib67","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic drug-drug interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib68","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.jpet.2025.103767_bib70","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/cancers16183176","article-title":"Combination of JAKi and HDACi exerts antiangiogenic potential in cutaneous T-cell lymphoma","volume":"16","author":"Karagianni","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103767_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248298","article-title":"Ruxolitinib with resminostat exert synergistic antitumor effects in cutaneous T-cell lymphoma","volume":"16","author":"Karagianni","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"Hosein","year":"2015","journal-title":"J Neurooncol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103767_bib73","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3390\/cells12081200","article-title":"The antiepileptic drug oxcarbazepine inhibits the growth of patient-derived isocitrate dehydrogenase mutant glioma stem-like cells","volume":"12","author":"Dao Trong","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.jpet.2025.103767_bib74","doi-asserted-by":"crossref","first-page":"14666","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpet.2025.103767_bib75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.actbio.2020.09.042","article-title":"Non-destructive tumor aggregate morphology and viability quantification at cellular resolution, during development and in response to drug","volume":"117","author":"Roberge","year":"2020","journal-title":"Acta Biomater"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102331","article-title":"Protocol for the generation and automated confocal imaging of whole multi-cellular tumor spheroids","volume":"4","author":"Genenger","year":"2023","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jpet.2025.103767_bib77","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.101886","article-title":"Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process","volume":"13","author":"Ning","year":"2025","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12935-021-01853-8","article-title":"Challenges of applying multicellular tumor spheroids in preclinical phase","volume":"21","author":"Han","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.jpet.2025.103767_bib79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2014.12.003","article-title":"Cancer multicellular spheroids: volume assessment from a single 2D projection","volume":"118","author":"Piccinini","year":"2015","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0022-1759(94)00239-S","article-title":"A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes","volume":"178","author":"Braut-Boucher","year":"1995","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.jpet.2025.103767_bib81","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0022-1759(94)90384-0","article-title":"Use of fluorescent dyes in the determination of adherence of human leucocytes to endothelial cells and the effect of fluorochromes on cellular function","volume":"172","author":"De Clerck","year":"1994","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1016\/j.jpet.2025.103767_bib82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.copbio.2012.01.011","article-title":"Synthetic 3D multicellular systems for drug development","volume":"23","author":"Rimann","year":"2012","journal-title":"Curr Opin Biotechnol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:02:08Z","timestamp":1777420928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022356525402808"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103767","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing local glioblastoma treatment via in vitro synergistic pairing of Janus kinase\/signal transducer and activator of transcription-3 inhibitor with antiepileptic drugs","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103767"}}